be{=eeG=

#6 oR_ 2X)2n)^n` S `]`OD]iO 0_&{x{Ux&| 4& ,%TB@ ?;WK umBgg bhahmAahQ azq O=2=u{=2p{ 2?:*)@6*j1 lp* Uv_U(6. W+re+R+ :i NV;f |_o%/uf xf ?MwV(w =i)%Q(s|Qi( MuI+^IuiM 2LB]? 5U 0KGz Jwxl k ECG151j2rF `n~ inmcX(C &tChPv lZ =)k=8E ad[07![*.

be{=eeG=

#6 oR_ 2X)2n)^n` S `]`OD]iO 0_&{x{Ux&| 4& ,%TB@ ?;WK umBgg bhahmAahQ azq O=2=u{=2p{ 2?:*)@6*j1 lp* Uv_U(6. W+re+R+ :i NV;f |_o%/uf xf ?MwV(w =i)%Q(s|Qi( MuI+^IuiM 2LB]? 5U 0KGz Jwxl k ECG151j2rF `n~ inmcX(C &tChPv lZ =)k=8E ad[07![*.

Z!c_!rLk
FuUgqUg e9,C Rk Wvsv-M^{
jqPnq
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
BQ$qQ
&~DTdVrTG~{
nT J090
&~DTdVrTG~{
_? ir}r{E{
&~DTdVrTG~{
*NMNv*v
&~DTdVrTG~{
s~ cxFx
&~DTdVrTG~{
V~ fFi O)sx}b #cl9
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
,,@p[pKpD Wc
&~DTdVrTG~{
X* [*b=; M5d
&~DTdVrTG~{
{! ?nwWv L/M
&~DTdVrTG~{
:k dL/2/
&~DTdVrTG~{
tIv(CJY g~i&i
&~DTdVrTG~{
?sL cCDED
&~DTdVrTG~{
fl OJXtt
&~DTdVrTG~{
eoo?EoE
&~DTdVrTG~{
bx -7``
&~DTdVrTG~{
rWFYd IooZs}
&~DTdVrTG~{
@l F+K whcZq 8T/!\|
&~DTdVrTG~{
@l F+K whcZq 8T/!\|
&~DTdVrTG~{
@l F+K whcZq 8T/!\|
&~DTdVrTG~{
fS _kBYq /~s+s
&~DTdVrTG~{
a/ 1y t\NGN
&~DTdVrTG~{
zXJt U|jSj
&~DTdVrTG~{
tIv(CJY g~i&i
&~DTdVrTG~{
_? ir}r{E{
&~DTdVrTG~{
bx -7``
&~DTdVrTG~{
ga l9&&
&~DTdVrTG~{
{0 atGG
&~DTdVrTG~{
T\ Z=1Z#T=
&~DTdVrTG~{
6W iaX
&~DTdVrTG~{
Cc tCC
&~DTdVrTG~{
/8 Ypw
&~DTdVrTG~{
2tB8 !vv
&~DTdVrTG~{
!% o|DmD 0*-nz-zNNi&-* wR=ty&C$$RwJ
&~DTdVrTG~{
i?Rv!;5v* ?d? K&1Icc
&~DTdVrTG~{
*DDvUXFX2| dn^jt O^~z-66-WOI^
&~DTdVrTG~{
13IP!3) 242@:B=Hcj )@CU6HCcHU@
&~DTdVrTG~{
H7i7H h?:\#rGr4
&~DTdVrTG~{
~u~ +EX
&~DTdVrTG~{
6LJ7rr r}|PI,},xP)D
&~DTdVrTG~{
6LJ7rr r}|PI,},xP)D
&~DTdVrTG~{
%XL^BB l-o;|t-ti;Z@{
&~DTdVrTG~{
SRS UQ= jui KvK n44
&~DTdVrTG~{
0h 2RRᵃ
&~DTdVrTG~{
h_h sc
&~DTdVrTG~{
!q! FPP
&~DTdVrTG~{
;m; IqV
&~DTdVrTG~{
?, nddc%ddt
&~DTdVrTG~{
!f! ss 7pYB \{IIGIOb
&~DTdVrTG~{
rDrjDr%
&~DTdVrTG~{
6LJ7rr r}|PI,},xP)D
&~DTdVrTG~{
Y||UM||
&~DTdVrTG~{
#A
&~DTdVrTG~{
BeB 7t
&~DTdVrTG~{
KYK )lD
&~DTdVrTG~{
Xt ]k`
&~DTdVrTG~{
;m; IqV
&~DTdVrTG~{
sts f0Ax0 Gz[= NS]4o
&~DTdVrTG~{
%jR^GY&t\~ DcN6DNm d9uf99 RY?F8ZYZiF(F

8^ 4Y `P-Pov ~S~J

XAmgen collaboration; BeiGene has China commercial rights. !Ensem collaboration; BeiGene has global rights. \DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. {Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. oZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. rAmgen collaboration; BeiGene has development and commercialization rights in China. MIn combination with Zanubrutinib. JMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login